van Oosterhout M, Verburg R J, Levarht E W N, Moolenburgh J D, Barge R M, Fibbe W E, van Laar J M
Department of Rheumatology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands.
Ann Rheum Dis. 2005 Dec;64(12):1783-5. doi: 10.1136/ard.2004.034793.
Immunoablative therapy combined with haematopoietic stem cell transplantation (SCT) is a possible treatment for patients with severe rheumatoid arthritis (RA).
A patient with rheumatoid factor positive, progressively erosive RA, refractive to treatment, was treated with high dose cyclophosphamide, followed by reinfusion of an unmanipulated peripheral blood graft derived from her identical twin sister. The clinical response was unsatisfactory, necessitating reinstitution of treatment with disease modifying antirheumatic drugs, which was associated with persistence of host serum autoantibodies and a cellular infiltrate in synovium, notably of plasma cells.
The effectiveness of syngeneic SCT may be critically dependent on the degree of immunoablation achieved or on the composition of the graft.
免疫清除疗法联合造血干细胞移植（SCT）是重度类风湿关节炎（RA）患者的一种可能治疗方法。
一名类风湿因子阳性、病情逐渐进展且侵蚀性强、对治疗耐药的RA患者，接受了高剂量环磷酰胺治疗，随后回输了来自其同卵双胞胎姐妹的未经处理的外周血移植物。临床反应不理想，需要重新使用改善病情抗风湿药物治疗，这与宿主血清自身抗体持续存在以及滑膜中有细胞浸润（尤其是浆细胞浸润）有关。
同基因SCT的有效性可能严重依赖于实现的免疫清除程度或移植物的组成。
